Digital From R&D to ROI: AI’s impact on pharma commercialisation AI in pharma commercialisation is transforming patient and healthcare provider engagement, streamlining regulatory reviews, and developing hyper-informed treatment pricing models, despite current scaling challenges.
News Sanofi abandons phase 3 trial of neurology drug riliprubart Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
